knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 01:08:54 - browse：775

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： CDC's new outbreak response network to include Northeastern

focus

WSS

A bus careens into a gulch in southern Mexico, leaving 27 people dead

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

How AI helped researchers track recovery from depression

Former New York Mayor de Blasio and wife announce separation, but not divorce

Ukraine and a new approach to mental health in war

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

leisure time

knowledge

Wikipedia

Novavax promises a turnaround & Lilly roils the obesity market

Intarcia’s device

BioMarin wins approval for gene therapy to treat hemophilia A

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Medical leaders decry Supreme Court decision on affirmative action

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Hepatitis C has a cure — but many Americans still lack access to it

What Congress can do to address the rural doctor shortage

Medicare proposal to cover medical devices draws a mixed reaction

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

focus

Senate HELP committee spars over health care workforce policies

CDC's new outbreak response network to include Northeastern

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

How Vertex's cystic fibrosis drug is changing patients' lives

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

focus

focus

leisure time

entertainment